Product image of Inzolfi (Fingolimod) supplied by GNH India

Inzolfi

Active Ingredient:
Fingolimod
Origin:
EU

Inzolfi (Fingolimod)

Fingolimod, the active ingredient in Inzolfi, is a sphingosine 1‑phosphate (S1P) receptor modulator presented as an oral formulation for oral use. It is indicated for the treatment of relapsing forms of multiple sclerosis in adult patients.
GNH India supplies Inzolfi as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Manufacturer / TM Owner

Sandoz Pharmaceuticals D.D.

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

  • Inzolfi is a sphingosine‑1‑phosphate receptor modulator used in the management of multiple sclerosis and related disease activity.
  • Relapsing‑remitting multiple sclerosis: reduces annual relapse rate and slows disability progression.
  • Active secondary progressive multiple sclerosis with relapses: delays worsening of disability.
  • Clinically isolated syndrome at high risk of conversion: decreases the likelihood of a second clinical event.

How It Works

  • Fingolimod selectively binds to sphingosine‑1‑phosphate receptors on lymphocytes, causing internalisation of the receptor complex. This sequesters lymphocytes within lymph nodes, preventing their egress into peripheral blood and thereby reducing immune‑mediated inflammation in the central nervous system characteristic of multiple sclerosis.

Side Effects

Fingolimod may cause a range of adverse reactions that vary in frequency and severity.

Common Side Effects

  • Headache: mild to moderate intensity.
  • Nasopharyngitis: upper respiratory tract infection symptoms.
  • Diarrhoea: loose stools, usually transient.
  • Fatigue: generalised tiredness.
  • Cough: dry or productive.
  • Elevated liver enzymes: mild transaminase increase.

Serious or Rare Side Effects

  • Herpes virus infections: reactivation risk.
  • Cardiac arrhythmia: bradycardia or conduction delays.
  • Macular edema: visual disturbances requiring ophthalmic monitoring.
  • Progressive multifocal leukoencephalopathy: rare opportunistic infection.
  • Severe liver injury: marked transaminase elevation.
  • Severe hypertension: significant blood pressure rise.

Precautions & Warnings

  • Before initiating therapy, clinicians should assess several safety parameters.
  • Baseline cardiac assessment: obtain ECG and monitor first dose for heart‑rate changes.
  • Vaccination status: avoid live vaccines during treatment and for at least two months after discontinuation.
  • Liver function monitoring: check transaminases periodically and adjust if significant elevation occurs.
  • Infection risk: monitor for signs of infection and counsel patients on prompt reporting.
  • Pregnancy considerations: discontinue therapy if pregnancy is confirmed and discuss contraception.
  • Store at ambient temperature: keep below 25°C in the original packaging, protect from moisture.

Avoid Interactions

Fingolimod can interact with other medicines, requiring careful management.

Major Interactions (Avoid)

  • Concomitant use with other S1P modulators: additive immunosuppression.
  • Strong CYP4F2 inhibitors: may increase fingolimod plasma concentrations.
  • Live attenuated vaccines: heightened risk of vaccine‑derived infection.

Moderate Interactions (Monitor Closely)

  • Beta‑blockers: may mask fingolimod‑induced bradycardia.
  • Antihypertensives: potential additive blood‑pressure lowering effect.
  • Non‑live vaccines: monitor immune response efficacy.

Frequently Asked Questions

Inzolfi contains fingolimod, an oral disease‑modifying therapy indicated for the treatment of relapsing forms of multiple sclerosis, including relapsing‑remitting and active secondary progressive disease.

Fingolimod binds to sphingosine‑1‑phosphate receptors on lymphocytes, causing their sequestration in lymph nodes. This reduces the number of circulating lymphocytes that can enter the central nervous system, thereby decreasing inflammatory activity that drives multiple sclerosis lesions.

The prescribed dose of Inzolfi is determined by the treating physician based on the patient’s clinical condition, weight, and safety considerations. Patients should follow the dosing instructions provided by their healthcare professional.

Fingolimod may pose risks to a developing fetus, and its safety in pregnancy has not been established. Women of child‑bearing potential should use effective contraception, and breastfeeding is not recommended while on therapy. Consultation with a specialist is essential.

To request Inzolfi, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and necessary import documentation.

Inzolfi (fingolimod) is an oral S1P receptor modulator, offering a convenient once‑daily tablet compared with injectable or infusion‑based disease‑modifying agents. Its efficacy in reducing relapse rates is comparable to some high‑efficacy therapies, but safety profiles differ, particularly regarding cardiac and infection risks.

Inzolfi should be stored at ambient temperature, below 25 °C, in its original packaging to protect it from moisture and light. Keep the product out of reach of children and do not store in bathrooms or near heat sources.

Inzolfi is taken orally, usually as a tablet swallowed whole with water. It is typically administered once daily, preferably at the same time each day, and should be taken with or without food as directed by the prescriber.

Serious risks include severe infections such as herpes virus reactivation, cardiac events like bradycardia or conduction abnormalities, macular edema affecting vision, and rare but severe liver injury. Patients should be monitored regularly for these potential complications.

Inzolfi is contraindicated in patients with known hypersensitivity to fingolimod, those with recent myocardial infarction, unstable angina, stroke, or uncontrolled cardiac disease, and individuals with active severe infections. It should also be avoided in pregnant women and in patients with significant liver impairment.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Fingolimod

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT